Clinical Trials in Clovis, California
21 recruiting
Showing 1–16 of 16 trials
Recruiting
Phase 3
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
National Cancer Institute (NCI)348 enrolled211 locationsNCT04530565
Recruiting
Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled576 locationsNCT03866382
Recruiting
Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Multiple Myeloma
Janssen Research & Development, LLC795 enrolled242 locationsNCT06208150
Recruiting
Phase 1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
B-cell Non Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRelapsed B-Cell Non Hodgkin Lymphoma
ADC Therapeutics S.A.200 enrolled42 locationsNCT04970901
Recruiting
Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRefractory B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)64 enrolled271 locationsNCT03739814
Recruiting
Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC1,590 enrolled261 locationsNCT05552222
Recruiting
Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Refractory Follicular LymphomaFollicular LymphomaRelapsed/Refractory Follicular Lymphoma
Epizyme, Inc.612 enrolled229 locationsNCT04224493
Recruiting
Phase 2
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
B-Cell Non-Hodgkins Lymphoma
Hoffmann-La Roche100 enrolled51 locationsNCT06806033
Recruiting
Phase 1Phase 2
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Cervical CancerUrothelial CarcinomaMelanoma+8 more
Bristol-Myers Squibb949 enrolled50 locationsNCT04895709
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled273 locationsNCT06152575
Recruiting
Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Multiple Myeloma
Pfizer944 enrolled239 locationsNCT05020236
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Gilead Sciences1,514 enrolled288 locationsNCT05633654
Recruiting
Phase 3
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
AbbVie170 enrolled70 locationsNCT06428019
Recruiting
Phase 3
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Peripheral T Cell Lymphoma
Acrotech Biopharma Inc.504 enrolled69 locationsNCT06072131
Recruiting
Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Stage IV Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8+2 more
SWOG Cancer Research Network1,273 enrolled338 locationsNCT03678025
Recruiting
Phase 2
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
Acute Myeloid LeukemiaRecurrent Acute Myeloid Leukemia
Brian Jonas20 enrolled4 locationsNCT04905810